TARSUS PHARMACEUTICALS INC (TARS) Stock Fundamental Analysis
USA - NASDAQ:TARS - US87650L1035 - Common Stock
68.25 USD
+0.16 (+0.23%)
68.25 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to TARS. TARS was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of TARS is average, but there are quite some concerns on its profitability. TARS shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TARS had negative earnings in the past year.
TARS had a negative operating cash flow in the past year.
In the past 5 years TARS always reported negative net income.
In the past 5 years TARS reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -18.58%, TARS is in the better half of the industry, outperforming 61.46% of the companies in the same industry.
The Return On Equity of TARS (-27.66%) is better than 61.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.58% | ||
| ROE | -27.66% | ||
| ROIC | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TARS has a better Gross Margin (93.36%) than 95.83% of its industry peers.
In the last couple of years the Gross Margin of TARS has remained more or less at the same level.
TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TARS has been increased compared to 1 year ago.
TARS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TARS is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 10.37 indicates that TARS is not in any danger for bankruptcy at the moment.
TARS has a better Altman-Z score (10.37) than 83.85% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that TARS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.22, TARS is in line with its industry, outperforming 44.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.37 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
A Current Ratio of 5.26 indicates that TARS has no problem at all paying its short term obligations.
TARS has a Current ratio of 5.26. This is in the better half of the industry: TARS outperforms 70.83% of its industry peers.
A Quick Ratio of 5.21 indicates that TARS has no problem at all paying its short term obligations.
TARS has a better Quick ratio (5.21) than 71.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.98%, which is quite impressive.
The Revenue has grown by 948.62% in the past year. This is a very strong growth!
TARS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.48% yearly.
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
Revenue 1Y (TTM)948.62%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
3.2 Future
Based on estimates for the next years, TARS will show a very strong growth in Earnings Per Share. The EPS will grow by 33.38% on average per year.
Based on estimates for the next years, TARS will show a very strong growth in Revenue. The Revenue will grow by 45.01% on average per year.
EPS Next Y48.35%
EPS Next 2Y55.72%
EPS Next 3Y44.46%
EPS Next 5Y33.38%
Revenue Next Year145.72%
Revenue Next 2Y91.93%
Revenue Next 3Y69.3%
Revenue Next 5Y45.01%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TARS. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 51.82 indicates a quite expensive valuation of TARS.
TARS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TARS is cheaper than 69.79% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, TARS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.82 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TARS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TARS's earnings are expected to grow with 44.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.72%
EPS Next 3Y44.46%
5. Dividend
5.1 Amount
No dividends for TARS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
68.25
+0.16 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners110.23%
Inst Owner Change-3.74%
Ins Owners3.27%
Ins Owner Change-0.15%
Market Cap2.88B
Revenue(TTM)182.95M
Net Income(TTM)-91.99M
Analysts87.14
Price Target80.14 (17.42%)
Short Float %17.9%
Short Ratio10.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.83%
Min EPS beat(2)-17.77%
Max EPS beat(2)14.11%
EPS beat(4)3
Avg EPS beat(4)13.91%
Min EPS beat(4)-17.77%
Max EPS beat(4)38.51%
EPS beat(8)7
Avg EPS beat(8)11.74%
EPS beat(12)10
Avg EPS beat(12)11.83%
EPS beat(16)12
Avg EPS beat(16)8.05%
Revenue beat(2)2
Avg Revenue beat(2)5.58%
Min Revenue beat(2)5.19%
Max Revenue beat(2)5.98%
Revenue beat(4)4
Avg Revenue beat(4)7.85%
Min Revenue beat(4)5.19%
Max Revenue beat(4)11.62%
Revenue beat(8)8
Avg Revenue beat(8)74.75%
Revenue beat(12)8
Avg Revenue beat(12)31.2%
Revenue beat(16)9
Avg Revenue beat(16)8.87%
PT rev (1m)6.59%
PT rev (3m)13.17%
EPS NQ rev (1m)3.88%
EPS NQ rev (3m)-14.57%
EPS NY rev (1m)-10.04%
EPS NY rev (3m)-32.35%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)10.08%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)7.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.82 | ||
| P/S | 9.75 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.66 | ||
| P/tB | 8.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.02
EYN/A
EPS(NY)1.32
Fwd EY1.93%
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS7
BVpS7.88
TBVpS7.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.58% | ||
| ROE | -27.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.36% | ||
| FCFM | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
F-Score5
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 426.34% | ||
| Cap/Sales | 2.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 10.37 |
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)439.33%
Cap/Depr(5y)393.66%
Cap/Sales(3y)12.37%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
EPS Next Y48.35%
EPS Next 2Y55.72%
EPS Next 3Y44.46%
EPS Next 5Y33.38%
Revenue 1Y (TTM)948.62%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
Revenue Next Year145.72%
Revenue Next 2Y91.93%
Revenue Next 3Y69.3%
Revenue Next 5Y45.01%
EBIT growth 1Y37.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.38%
EBIT Next 3Y55.5%
EBIT Next 5Y22.13%
FCF growth 1Y-14.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.43%
OCF growth 3YN/A
OCF growth 5YN/A
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you provide the ChartMill fundamental rating for TARSUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to TARS.
What is the valuation status of TARSUS PHARMACEUTICALS INC (TARS) stock?
ChartMill assigns a valuation rating of 2 / 10 to TARSUS PHARMACEUTICALS INC (TARS). This can be considered as Overvalued.
Can you provide the profitability details for TARSUS PHARMACEUTICALS INC?
TARSUS PHARMACEUTICALS INC (TARS) has a profitability rating of 2 / 10.
Can you provide the financial health for TARS stock?
The financial health rating of TARSUS PHARMACEUTICALS INC (TARS) is 5 / 10.
Can you provide the expected EPS growth for TARS stock?
The Earnings per Share (EPS) of TARSUS PHARMACEUTICALS INC (TARS) is expected to grow by 48.35% in the next year.